SalezShark Logo

BerGenBio ASA Employee Emails and Contacts

Company Logo

BerGenBio ASA

BerGenBio is a clinical-stage biopharmaceutical company focused on developing a pipeline of first-in-class selective AXL kinase inhibitors to treat multiple aggressive cancers. The Company is a world leader in understanding ...

Detailed Overview of BerGenBio ASA | Emails & Phone

  • Company Name

    BerGenBio ASA

  • Official Contact

    ******6881

  • Official Address

    Jonas Lies vei 91, Bergen, Hordaland, Norway, 5009... More

  • Industry Type

    Pharmaceuticals

  • Employees Range

    51 - 100

  • Revenue Range

    51 - 100

  • Company Type

    Public Company

  • Official Website

    http://www.bergenbio.com

  • Products/Services

    Drug discovery , Drug target discovery , Aggressiv... More

BerGenBio ASA - Designation, Email Address and Phone Numbers

Check the Email and Phone Number List of the Top Management working at the BerGenBio ASA

NameDesignationEmail AddressContact NumberView Email & Phone
Nigel McCrackenChief Scientific Officer****@bergenbio.com******7277 View Email & Phone
DesignationsCompany Logo

How do Emails and Phone Numbers of BerGenBio ASA Help in Bringing Leads?

After viewing all the BerGenBio ASA employees' emails like the emails of the O Level, CXO, HR Head Email, Admin, Management, Managing Director,Founder, Sales Head, CFO Contact, CEO, Marketing Head, and other Key Employees you can use the Connect+ Email Marketing Tool to send them bulk emails and generate leads. BerGenBio ASA has a revenue of 51 - 100 and 51 - 100 employees are working at Dabur to whom you can hit the emails.

Frequently Asked Questions

The headquarters of BerGenBio ASA is in Hordaland, Norway

The Official Website of the BerGenBio ASA is http://www.bergenbio.com

The Industry type of BerGenBio ASA is Pharmaceuticals

The overall employees at BerGenBio ASA are 51 - 100

BerGenBio ASA generates an income of 51 - 100 in a year

The products and services offered by BerGenBio ASA are Drug discovery , Drug target discovery , Aggressive, drug-resistant cancer , AXL , oncology , acute myeloid leukaemia , Non-small cell lung cancer

Go to top